Device Authority targets enterprise IoT security demand through Xalient partnership

Tern plc

Device Authority has partnered with Xalient to strengthen IoT security for enterprise customers, with its KeyScaler platform being added to Xalient’s managed cybersecurity services.

The partnership is designed to help large organisations secure connected devices more effectively, particularly where IoT and operational technology assets are spread across complex environments. Device Authority is being positioned inside a managed enterprise security offering, giving it a clearer route to customers that need scalable device identity and access management.

Xalient provides identity-led cybersecurity and managed security services. By integrating Device Authority’s KeyScaler technology, it will be able to offer automated protection for connected devices across their full lifecycle. This includes device onboarding, credential management, certificate rotation, access control and decommissioning.

These are practical security functions for enterprises. As more organisations connect equipment, sensors, machines and operational systems, the number of devices that need to be identified, authenticated and managed continues to grow. Manual processes are difficult to scale and can increase risk. Automated device identity management helps reduce gaps in visibility and control.

The partnership focuses on sectors where secure connected infrastructure matters. Energy and utilities, manufacturing, healthcare and critical infrastructure often run large device networks where downtime, unauthorised access or weak credential management can create operational and compliance risks.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Talking Medicines targets a growing data need around GLP-1 treatment journeys

Talking Medicines is using GLP-1 discontinuation conversations to show how DrugVoice can help pharmaceutical companies track changing patient needs across the treatment journey.

Device Authority adopts usage-based pricing to support KeyScaler expansion

Device Authority has moved KeyScaler to usage-based pricing, aiming to reduce licensing friction and support broader adoption of its machine identity security platform.

Talking Medicines targets growing demand for GLP-1 patient intelligence

Talking Medicines is using GLP-1 patient conversations to show how behavioural data can help pharmaceutical companies understand changing treatment expectations and engagement.

Talking Medicines builds its AI strategy around specialist life sciences intelligence

Talking Medicines is positioning specialist healthcare intelligence as the core layer that gives agentic AI useful context in life sciences.

Search